International Journal of Clinical Research

Objective To explore the clinical efficacy and safety of levamlodipine besylate tablets combined with telmisartan in the treatment of elderly patients with hypertension. Methods From January 2023 to January 2024, 100 elderly patients with hypertension were selected in our hospital and grouped according to the treatment methods, with 50 cases in each group. The two groups were respectively treated with levamlodipine besylate tablets as monotherapy (control group) and levamlodipine besylate tablets combined with telmisartan (observation group). The therapeutic effects of the two groups were determined after continuous treatment for 12 weeks. Results After 12 weeks of treatment, the SBP and DBP in both groups were significantly lower than those before treatment (P<0.05). Moreover, the SBP (132.5±7.8 mmHg) and DBP (82.3±5.6 mmHg) in the observation group were both lower than those in the control group (145.2±8.5 mmHg, 89.6±6.1 mmHg) (P<0.05). The total effective rate of treatment in the observation group (94.00%) was significantly higher than that in the control group (78.00%) (P<0.05). Comparison of the incidence of adverse reactions between the two groups (observation group 8.00% vs control group 10.00%) (P>0.05). Conclusion The combination of levamlodipine besylate tablets and telmisartan in the treatment of elderly hypertension can more effectively lower blood pressure, improve clinical efficacy, and has good safety. It is suitable for long-term application in elderly patients.

Hypertension in the elderly; Levamlodipine besylate; Tablets Telmisartan; Combination therapy; Blood pressure control